A5038747590- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Childhood Cancer Survivors' Quality of Life
- T-cell and B-cell Immunology
- Parvovirus B19 Infection Studies
- Renal Transplantation Outcomes and Treatments
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Transplantation: Methods and Outcomes
- Herpesvirus Infections and Treatments
- Autoimmune and Inflammatory Disorders Research
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
Hôpital Saint-Antoine
2016-2024
Sorbonne Université
2016-2024
Assistance Publique – Hôpitaux de Paris
2017-2024
Institut Català d'Oncologia
2021-2024
Institut d'Investigació Biomédica de Bellvitge
2021-2024
Università Campus Bio-Medico
2012-2024
Duran i Reynals Hospital
2021-2024
Josep Carreras Leukaemia Research Institute
2024
Hospital de Sant Pau
2024
Universitat Autònoma de Barcelona
2024
Post-transplant cyclophosphamide (PT-Cy) has become a standard of care in haploidentical hematopoietic stem cell transplantation (HSCT) to reduce the risk graft-versus-host disease. However, data on cardiac events associated with PT-Cy are scarce.This study sought assess incidence and clinical features PT-Cy.The compared outcomes between patients who received (n = 136) did not 195), focus early (ECE) occurring within first 100 days after HSCT. All had same systematic monitoring.The...
Key Points A 6-year overall survival of 61% was observed in leukodystrophy patients after cord blood transplantation. Mismatched donors, symptomatic disease, and lower PS before transplantation were predictors survival.
We report the outcomes of 51 patients who underwent unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-Cy) and antithymocyte globulin (ATG), from peripheral blood cells (PBSCs) or bone marrow, after receipt a TBF (thiotepa, busulfan, fludarabine) conditioning regimen. Their median age was 55 years (range, 16 to 72 years). Hematologic diagnoses included acute leukemias (n = 31), lymphoid neoplasm 12),...
Despite effective treatments, cytomegalovirus (CMV) continues to have a significant impact on morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients. This multicenter, retrospective, cohort study aimed evaluate the reproducibility of safety efficacy commercially available letermovir for CMV prophylaxis real-world setting. Endpoints were rates clinically infection (CSCI), defined as disease or viremia reactivation within day +100-+168. 204 adult CMV-seropositive...
Abstract Background Human metapneumovirus (hMPV) epidemiology, clinical characteristics and risk factors for poor outcome after allogeneic stem cell transplantation (allo-HCT) remain a poorly investigated area. Methods This retrospective multicenter cohort study examined the characteristics, outcomes associated with human infections in recipients of allo-HCT. Results We included 428 allo-HCT who developed 438 hMPV infection episodes between January 2012 2019. Most were adults (93%)....
Body mass index (BMI) may influence outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). However, the impact of BMI on survival in children undergoing HSCT is not well defined, with conflicting results being reported this issue. We analyzed 855 patients age 2 to 20 years diagnosis acute leukemia who underwent umbilical cord blood (UCBT) from 1990 2015. Patients were classified according as normal (fifth 85th percentile), underweight (less than fifth overweight (85th 95th...
Post-transplant cyclophosphamide (PTCY) has been introduced as graft-versus-host disease (GvHD) prophylaxis in mismatched and matched unrelated hematopoietic cell transplant (HCT). However, data comparing outcomes of PTCY or ATG patients undergoing a 1 antigen HCT for lymphoproliferative are limited. We compared versus adult with first 9/10 MMUD reduced intensity conditioning regimen from 2010 to 2021. Patients receiving were according to: age, status at transplant, female male matching,...
Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for most children with osteopetrosis (OP). Timing of HSCT critical; therefore, umbilical cord blood (UCBT) an attractive option. We analyzed outcomes after UCBT in 51 OP children. Median age at was 6 months. Seventy-seven percent grafts had 0 or 1 HLA disparity recipient. Conditioning regimen myeloablative (mostly busulfan-based 84% and treosulfan-based 10%). Antithymocyte globulin given to 90% patients. number...
Although allogeneic stem cell transplantation is not a standard therapy for multiple myeloma, some patients can benefit from this intense therapy. There are few reports on outcomes after umbilical cord blood in and investigation of procedure warranted. We retrospectively analyzed 95 patients, 85 with myeloma 10 plasma leukemia, receiving single or double 2001 to 2013. Median follow up was 41 months. The majority received reduced intensity conditioning. cumulative incidence neutrophil...
Abstract Objectives This retrospective study analyzed the impact of early cyclosporine A (CsA) initiation (day −3) on risk acute graft‐vs‐host disease (aGvHD) after haploidentical hematopoietic cell transplantation (Haplo‐HCT) using post‐transplant cyclophosphamide. Methods Sixty‐one consecutives patients who underwent Haplo‐HCT were analyzed. Results At day +180, cumulative incidences grade II‐IV and III‐IV aGvHD 39% 18%, respectively. Patients having a lowest CsA concentration (<301...
Background: We aimed to assess the incidence, etiology and outcomes of catheter-related bloodstream infection (CRBSI) in onco-hematological patients, differences between patients with hematological malignancies (HMs) solid tumors (STs) identify risk factors for Gram-negative (GN) CRBSI. Methods: All consecutive episodes BSI adult cancer were prospectively collected (2006-2020). The CRBSI was analyzed three different 5-year periods. Risk GN assessed whole cohort separately HMs STs. Results:...
Human herpesvirus type 6 (HHV6) reactivation after haploidentical hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) has been scarcely studied, especially when antithymocyte globulin (ATG) is added to the graft-versus-host disease (GvHD) prophylaxis. We conducted a retrospective cohort study in 100 consecutive patients receiving HCT PT-Cy. systematically monitored HHV6 DNA loads blood samples on weekly basis using quantitative PCR until day +100. The...
Patients with hematological malignancies receiving hematopoietic cell transplantation (HCT) or chimeric antigen receptor (CAR) T-cell therapy are at risk of developing serious clinical complications after discharge.
Cell therapy, specifically the revolutionary chimeric antigen receptor (CAR) T-cell has transformed landscape of oncology, making substantial strides in practical treatment approaches. Today, established guidelines for diseases such as lymphomas, myelomas, and leukemias actively advocate utilization these once-unconventional therapies. The impact therapies is underscored by their unparalleled efficacy, reshaping way we approach implement treatments realm oncology. However, CAR with its...
Smoldering multiple myeloma (SMM) presents a high risk of progression to symptomatic MM (sy-MM). Herein, we analyzed some predictors development sy-MM. In 144 patients with SMM, also compared the predicted by bone marrow plasma cell (BMPC) involvement on biopsy (BMB) versus aspirates (BMA).From January 1980 July 2010, 397 SMM observed in 12 centers Multiple Myeloma GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Latium Working Group have been analyzed. At sy-MM, severity clinical...
Efforts to implement family cord blood banking have been developed in the past decades for siblings requiring stem cell transplantation conditions such as sickle disease. However, public banks are faced with challenging decisions about units be stored, discarded, or used other endeavors. We report here 20 years of experience disease two dedicated banks. Participants were pregnant women who had a previous child diagnosed homozygous Participation was voluntary and free charge. All mothers...